Mock Sekine, Mizuna

Mizuna Sekine

Associate

She/Her/Hers

mizuna.sekine@lw.com
    Mock Sekine, Mizuna

    Mizuna Sekine

    Associate

    mizuna.sekine@lw.com

    Profile

    Mizuna Sekine is an associate in the Bay Area offices of Latham & Watkins and a member of Latham’s Corporate Department and Healthcare & Life Sciences Practice.

    Mizuna advises private and public companies primarily in the life sciences area in various transactional matters, including licenses, collaborations, technology transfer, mergers, acquisitions, and public offerings.

    Mizuna brings clients technical insight coupled with her passion for bringing innovation to market. She regularly advises clients on matters including:

    • Intellectual property and technology licenses
    • Joint ventures and strategic alliances
    • Venture financings, public offerings, M&A, and other strategic transactions
    • Manufacturing, supply, distribution, and other commercial agreements
    • Research, development, and clinical trial agreements

    Mizuna earned a Master of Chemistry degree at Oxford University (Trinity College) for her work in Dr. Colin Bain’s laboratory on chemistry of surfaces and interfaces. She is registered to practice before the United States Patent and Trademark Office (USPTO) and is a Certified Information Privacy Professional in both Europe (CIPP/E) and the United States (CIPP/US).

    Mizuna maintains an active pro bono practice, regularly advising non-profit organizations in relation to their regulatory and commercial needs.

    Experience

    Mizuna’s experience includes advising:

    • CARGO Therapeutics in its initial public offering on the Nasdaq Global Select Market and its subsequent acquisition by Concentra Biosciences
    • Coherus BioSciences in its:
      • US$558.4 million divestment of the UDENYCA (pegfilgrastim-cbqv) franchise to Intas Pharmaceuticals Ltd.
      • US$40 million divestment of YUSIMRY (adalimumab-aqvh) to Hong Kong King-Friend Industrial Co. Ltd.
      • US$76.2 million combined term loan and product royalty financing agreement with Barings
    • A global biotechnology company developing vaccines in its collaboration and license arrangement with a Japanese multinational pharmaceutical company for its COVID-19 vaccine candidate
    • A leading biotechnology company in its collaboration and license arrangement with a biotechnology company for developing and commercializing medicine for the treatment of Dravet syndrome
    • A medical device company on its joint venture with a leading global healthcare investment firm and a medical device platform incubated by such investment firm, to manufacture and commercialize its medical devices in Greater China
    • CeriBell in its upsized initial public offering on the Nasdaq Global Select Market 
    • PROCEPT BioRobotics Corporation in its follow-on offering of its common stock
    • Seres Therapeutics in its sale of its VOWST business to Nestlé Health Science 
    • Pionyr Immunotherapeutics in its acquisition by Ikena Oncology
    • Revolution Medicines in its US$2 billion growth financing with Royalty Pharma
    • Verona Pharma in its US$650 million strategic financing with Oaktree and OMERS
    • Ascendis Pharma A/S in its US$150 million capped synthetic royalty funding agreement with Royalty Pharma
    • Arcus Biosciences in its US$250 million strategic financing with Hercules Capital
    • scPharmaceuticals in its US$125 million strategic financing with Perceptive Advisors

    Qualifications

    Bar Qualification

    • California
    • England and Wales (Solicitor)
    • New York
    • US Patent and Trademark Office

    Education

    • LL.M., Stanford Law School
    • Diploma, The Legal Training and Research Institute of Japan
    • J.D., Keio University
    • M.Chem in Chemistry, University of Oxford

    Languages Spoken

    • English
    • Japanese

    Practices

    Industries

    News & Insights

    Read More